# US 2020/0399329 A1 · Antimicrobial peptides > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2020/0399329 A1 - Document ID: US20200399329A1 - Status: Published application - Kind: A1 - Application number: 16/986,463 - Filed: 2020-08-06 - Published: 2020-12-24 - Earliest claimed: 2015-02-22 - Assignees: Omnix Medical Ltd. - Applicants: Omnix Medical Ltd. - Inventors: Niv BACHNOFF; Moshe COHEN-KUTNER - Web page: https://patentgrep.com/patent/US20200399329A1 ## CPC - C07K 14/43563: {from insects} - A61K 38/1767: {from invertebrates} - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - C07K 14/43536: {from worms} - C07K 14/4354: {from nematodes} - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The invention provides a peptide comprising: a core amino acid sequence, which is identical or similar to the amino acid sequence of a member of the Cecropin family. The invention further provides a nucleic acid sequence encoding the peptide and a vector comprising said nucleic acid. The invention further provides a pharmaceutical composition comprising said peptide or said nucleic acid. The invention further provides methods of treating an infection, overcoming inherent or acquired resistance of a microorganism to an antibiotic agent or disinfecting a wound, the methods comprises administering the peptide to a subject in need thereof. ## Claims ### Claim 1 A cyclic peptide that has an amino acid sequence having at least 95% sequence identity to the amino acid sequence set forth in SEO ID NO: 9. ### Claim 2 (depends on 1) The cyclic peptide according to claim 1, wherein the amino acid sequence has at least 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 9. ### Claim 3 (depends on 1) The cyclic peptide of claim 1, wherein the peptide is as set forth in SEQ ID NO:9. ### Claim 4 (depends on 1) A pharmaceutical composition comprising the cyclic peptide of claim 1. ### Claim 5 (depends on 1) A method of treating a bacterial infection, the method comprising administering the cyclic peptide of claim 1 to a subject in need thereof, wherein the bacterial infection is caused by a gram-negative bacteria. ### Claim 6 (depends on 5) The method of claim 5, wherein the in need thereof, wherein the gram-negative bacteria is Enterobacteriaceae spp., Pseudomonas spp. Salmonella spp., E. coli spp., K. pneumoniae spp, or any combination thereof. ### Claim 7 (depends on 4) The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is in a form of a liquid, cream, gel, paste, powder, emulsion, an ointment, a liniment, a lotion, a transdermal system, an injection fluid, a suspension, a film patch or spray. ### Claim 8 (depends on 4) The pharmaceutical composition of claim 4, which is in the form of a capsule or a tablet. ### Claim 9 (depends on 1) A pharmaceutical composition comprising the cyclic peptide of claim 1 in combination with one or more anti-inflammatory active agents or one or more antibiotic agents or any combination thereof. ### Claim 10 (depends on 1) A method of overcoming inherent or acquired resistance of a gram-negative bacteria to an antibiotic agent, comprising: contacting the gram-negative bacteria with the cyclic peptide of claim 1. ### Claim 11 (depends on 10) The method of claim 10, wherein the bacteria is a drug-sensitive or drug-resistant member of Klebsiella pneumoniae spp., E. coli. spp., Pseudomonas aeruginosa spp., Salmonella spp. and Enterobacteriaceae spp combination thereof. ### Claim 12 (depends on 10) The method of claim 10, wherein the bacteria is E. coli MDR, E. coli ESBL, E. coli CR, K. pneumoniae MDR, K. pneumoniae KPC, K. pneumoniae NDM1, K. pneumoniae ESBL, P. aeruginosa MDR, Salmonella MDR or any combination thereof. ### Claim 13 (depends on 1) A method of disinfecting a cutaneous abscess comprising contacting the cutaneous abscess with the cyclic peptide of claim 1, wherein an infection in the cutaneous abscess caused by gram negative bacteria.